Robert P. Frantz

Robert P. Frantz

Auto-generated profile, based on publicly available information

Robert P. Frantz

Mayo Clinic

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in JACC
Verified
Journal Article
Closed access
MHMarius Hoeper
Marius Hoeper
HBHarm Jan Bogaard
Harm Jan Bogaard
RCRobin Condliffe
Robin Condliffe
RFRobert Frantz
Robert Frantz
DKDinesh Khanna
Dinesh Khanna
DBDavid B. Badesch
David B. Badesch

13 July 2010 in Circulation
Verified
Journal Article
Open access
PDF file
RBRaymond l Benza
Raymond l Benza
DMDave P. Miller
Dave P. Miller
MGMardi Gomberg-Maitland
Mardi Gomberg-Maitland
RFRobert P. Frantz
Robert P. Frantz
AFAimee J. Foreman
Aimee J. Foreman
MMMichael D. McGoon
Michael D. McGoon
Background— Factors that determine survival in pulmonary arterial hypertension (PAH) drive clinical management. A quantitative survival prediction tool has not been established for research or clinical use. Methods and Results— Data from 2716 patients with PAH enrolled consecutively in the US Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) were analyzed to assess predictors of 1-year survival. We identified independent prognosticators of survival and derived a multivariable, weighted risk formula for clinical use. One-year survival from the date of enrollment was 91.0% (95% confidence interval [CI], 89.9 to 92.1). In a multivariable analysis with Cox proportional hazards, variables independently associated with increased mortality included pulmonary vascular resistance >32 Wood units (hazard ratio [HR], 4.1; 95% CI, 2.0 to 8.3), PAH associated with portal hypertension (HR, 3.6; 95% CI, 2.4 to 5.4), modified New York Heart Association/World Health Organization functional class IV (HR, 3.1; 95% CI, 2.2 to 4.4), men >60 years of age (HR, 2.2; 95% CI, 1.6 to 3.0), and family history of PAH (HR, 2.2; 95% CI, 1.2 to 4.0). Renal insufficiency, PAH associated with connective tissue disease, functional class III, mean right atrial pressure, resting systolic blood pressure and heart rate, 6-minute walk distance, brain natriuretic peptide, percent predicted carbon monoxide diffusing capacity, and pericardial effusion on echocardiogram all predicted mortality. Based on these multivariable analyses, a prognostic equation was derived and validated by bootstrapping technique. Conclusions— We identified key predictors of survival based on the patient’s most recent evaluation and formulated a contemporary prognostic equation. Use of this tool may allow the individualization and optimization of therapeutic strategies. Serial follow-up and reassessment are warranted. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00370214.

24 January 2019 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
NGNazzareno Galiè
Nazzareno Galiè
RCRichard N. Channick
Richard N. Channick
RFRobert P. Frantz
Robert P. Frantz
EGEkkehard Grünig
Ekkehard Grünig
Zhi-Cheng JingZhi-Cheng Jing
Zhi-Cheng Jing
VMVallerie V. McLaughlin
Vallerie V. McLaughlin
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.

1 August 2019 in Chest
Verified
Journal Article
Open access
RBRaymond L. Benza
Raymond L. Benza
MGMardi Gomberg-Maitland
Mardi Gomberg-Maitland
CEC. Greg Elliott
C. Greg Elliott
HFHarrison W. Farber
Harrison W. Farber
AFAimee J. Foreman
Aimee J. Foreman
RFRobert P. Frantz
Robert P. Frantz
Pulmonary arterial hypertension is a progressive, fatal disease. Published treatment guidelines recommend treatment escalation on the basis of regular patient assessment with the goal of achieving or maintaining low-risk status. Various strategies are available to determine risk status. This analysis describes an update of the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk calculator (REVEAL 2.0) and compares it with recently published European Society of Cardiology/Respiratory Society guideline-derived risk assessment strategies. A subpopulation from the US-based registry REVEAL that survived ≥ 1 year postenrollment (baseline for this cohort) was analyzed. For REVEAL 2.0, point values and cutpoints were reassessed, and new variables were evaluated. The Kaplan-Meier method was used to estimate survival at 12 months postbaseline; discrimination was quantified using the c-statistic. Mortality estimates and discrimination were compared between REVEAL 2.0 and Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) and French Pulmonary Hypertension Registry (FPHR) risk assessment strategies. For this comparison, a three-category REVEAL 2.0 score was computed in which patients were classified as low-, intermediate-, or high-risk. REVEAL 2.0 demonstrated similar discrimination as the original calculator in this subpopulation (c-statistic = 0.76 vs 0.74), provided excellent separation of risk among the risk categories, and predicted clinical worsening as well as mortality in patients who were followed ≥ 1 year. The REVEAL 2.0 three-category score had greater discrimination (c-statistic = 0.73) than COMPERA (c-statistic = 0.62) or FPHR (c-statistic = 0.64). Compared with REVEAL 2.0, COMPERA and FPHR both underestimated and overestimated risk. REVEAL 2.0 demonstrates greater risk discrimination than the COMPERA and FPHR risk assessment strategies in patients enrolled in REVEAL. After external validation, the REVEAL 2.0 calculator can assist clinicians and patients in making informed treatment decisions on the basis of individual risk profiles. ClinicalTrials.gov; No. NCT00370214; URL: www.clinicaltrials.gov.

1 February 2012 in Chest
Verified
Journal Article
Closed access
PDF file
RBRaymond l Benza
Raymond l Benza
MGMardi Gomberg-Maitland
Mardi Gomberg-Maitland
DMDave P. Miller
Dave P. Miller
AFAdaani Frost
Adaani Frost
RFRobert P. Frantz
Robert P. Frantz
MMMichael D. McGoon
Michael D. McGoon

1 September 2013 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
NFNowell M. Fine
Nowell M. Fine
LCLibo Chen
Libo Chen
PBPaul M. Bastiansen
Paul M. Bastiansen
RFRobert P. Frantz
Robert P. Frantz
PPPatricia A. Pellikka
Patricia A. Pellikka
GKGarvan C. Kane
Garvan C. Kane
Background—: Although right ventricular (RV) dysfunction is a major determinant of outcome in patients with pulmonary hypertension (PH), the optimal measure of RV function is poorly defined. We hypothesized that RV strain measured by speckle-tracking echocardiography predicts outcome in PH over a broad range of pulmonary pressures. Methods and Results—: Prospective peak RV longitudinal systolic strain measurement was performed on 575 patients (mean age, 56±18 years; 63% women) referred for echocardiography for known or suspected PH. Survival status was assessed over a median of 16.5 (interquartile range, 7.6–20.0) months. There were 406 patients with PH (71%) (74% group 1, 14% group 3, and 12% group 4) and 169 patients without evidence of PH (29%). Among patients with PH, 46% were World Health Organization functional class III–IV. The mean RV strain was −21.2±6.7% for all patients. RV strain declined with worse functional class, shorter 6-minute walk distances, higher N-terminal pro-B-type natriuretic peptide levels, and the presence of right heart failure. RV strain predicted outcome across pulmonary pressures and groups of PH. Eighteen-month survival was 92%, 88%, 85%, and 71% according to RV strain quartile ( P <0.001), with a 1.46 higher risk of death (95% confidence interval, 1.05–2.12) per 6.7% decline in RV strain. RV strain predicted survival when adjusted for pulmonary pressure, pulmonary vascular resistance, and right atrial pressure and provided incremental prognostic value over conventional clinical and echocardiographic variables. Conclusions—: Quantitative assessment of RV free-wall systolic strain is feasible and is a powerful predictor of the clinical outcome of patients with known or suspected PH.